News
Market and company headlines
BHVNAll
Loading
03:00Yesterday1 Story
07:00-12:00Oct 232 Stories
Biohaven Could Transform With Troriluzole's FDA Approval, RBC Says
Biohaven (BHVN) securing approval for troriluzole could transform the company, potentially unlocking
Why Biohaven (BHVN) Is Up 25.0% And What's Next After FDA Review Acceptance
Biohaven secured FDA acceptance of its resubmitted new drug application for Vyglxia, or troriluzole, in spinocerebellar ataxia, with a planned advisory committee review and a user fee goal date set in Q1 2027. The firm also signed a licensing and collaboration deal with Ono Pharmaceutical for its MoDE pan IgG degrader portfolio in select Asian markets. This supports funding and regional execution for programs such as BHV-1300 for Graves' disease. The focus now shifts to how Biohaven's...
05:00Oct 231 Story
16:00-23:00Oct 222 Stories
Biohaven (BHVN) Soars 25% on FDA Drug Review, Price Target Upgrade
Biohaven Ltd (NYSE:BHVN) soared up to 25.02 percent on Thursday, closing at $14.69 apiece, as investors gobbled up shares after its drug candidate for spinocerebellar ataxia (SCA) moved closer to commercialization. This followed a regulatory filing on the same day the Food and Drug Administration (FDA) officially accepted for review the listed firm’s resubmitted new […]
Why Biohaven Catapulted 25% — And Why It Might Not Be Done Sprinting
Biohaven stock catapulted Thursday after the FDA said it would review the company's embattled drug, troriluzole.
12:00-14:00Oct 222 Stories
Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again
The Food and Drug Administration agrees to review a New Drug Application for Vyglxia, Biohaven’s experimental spinocerebellar ataxia treatment.
Biohaven’s previously rejected rare disease drug to get fresh FDA review
U.S. regulators have accepted a new submission for Vyglxia, offering the chance at a turnaround for another rare disease medicine spurned by previous FDA leadership.
09:00Oct 221 Story
05:00Oct 91 Story
04:00-09:00Oct 82 Stories
Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement
Biohaven signs a $100 million Asian licensing agreement with Ono Pharmaceutical for its Phase 3 MoDE pan IgG degrader portfolio.
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
Biohaven Ltd. together with its wholly owned subsidiaries, ("Biohaven") (NYSE: BHVN) today announced that it has entered into a strategic licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd. ("Ono") (TYO: 4528), under which Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE™ pan IgG degrader portfolio, led by BHV-1300 and including next-generation follow-on degraders BHV-1310 and BHV-1320, in Japan, South Korea, Taiwan, and the countries of the A
00:00-03:00Oct 82 Stories
Is Biohaven (BHVN) Quietly Recasting Its Oncology Strategy Through Deeper Ties With Regeneron?
In September 2026, Biohaven Ltd. announced a clinical supply agreement with Regeneron Pharmaceuticals to test BHV-1530 in combination with cemiplimab (Libtayo) in patients with solid tumors, following earlier monotherapy and preclinical data suggesting potential synergy with Anti-PD-1 therapy. This new BHV-1530 collaboration builds on an existing supply agreement for Biohaven’s next-generation TROP2-directed ADC BHV-1510, deepening Regeneron’s involvement across Biohaven’s oncology...
Biohaven Licenses MoDE IgG Degraders To Ono For Japan, South Korea, Taiwan And ASEAN For Up To $100M Near-Term Payments Including $80M Upfront; BHV-1300 In Phase 3 For Graves' Disease
Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states, led by BHV-1300 and including certain next-generation
09:00Oct 21 Story
03:00-08:00Sep 282 Stories
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced that data on BHV-1530, its FGFR3-directed antibody-drug conjugate (ADC) using a novel topoisomerase I (TopoIx) payload, have been accepted for an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 202
Biohaven To Present Data On BHV-1530, FGFR3-Directed ADC Using Topoisomerase I Payload, At 38th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics
Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), a
17:00Sep 251 Story
13:00-15:00Sep 182 Stories
Xenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain.
Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar depression following ‘adverse events.’
Warby Parker’s Unusual Options Activity Points to a Covered Call Bet: Bullish on Growth, Cautious on Valuation
Warby Parker's 1,500-contract December $22.50 call trade, tied to a stock purchase, signals an institutional covered call. The setup looks bullish on growth and earnings, but a rich valuation, slowing customer growth, and rising capex limit the stock's potential upside.
04:00-09:00Sep 182 Stories
Xenon Stock Craters on Drug Trial Setback. Its Failure Could Be This Rival’s Gain.
Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar depression following ‘adverse events.’
Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. futures rise, but Xenon plunges 27.6% after pausing psychiatry trial enrollment over neuropsychiatric adverse events; other stocks also fall
00:00Sep 181 Story
07:00Sep 111 Story
14:00-17:00Sep 102 Stories
Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback
Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment due to safety concerns.
Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.
Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit.